# China NMPA Drug Inspection - Bozhou Baisheng Pharmaceutical Co., Ltd. - silkworm

Source: https://www.globalkeysolutions.net/records/china_drug_inspection/bozhou-baisheng-pharmaceutical-co-ltd/a7b4d816-b824-4424-8a13-6321332fd2f4/
Source feed: China

> China NMPA drug inspection for Bozhou Baisheng Pharmaceutical Co., Ltd. published January 17, 2017. Drug: silkworm. The Henan Provincial Food and Drug Administration in China issued a drug quality announcement on January 17, 2017, detai

---

## Details

- Record Type: CHINA_DRUG_INSPECTION
- Title: Henan Province Drug Quality Bulletin (Issue No. 43)
- Company Name: Bozhou Baisheng Pharmaceutical Co., Ltd.
- Publication Date: 2017-01-17
- Drug Name: silkworm
- Inspection Finding: Check total ash content
- Action Taken: Local authorities should investigate and handle these cases in accordance with the relevant provisions of the "Drug Administration Law of the People's Republic of China".
- Summary: The Henan Provincial Food and Drug Administration in China issued a drug quality announcement on January 17, 2017, detailing findings from supervisory sampling inspections. These inspections were conducted to enhance drug quality oversight and protect public health within Henan Province. The announcement identified 46 batches of drugs that failed to meet established quality standards, originating from numerous manufacturers and dispensed at various pharmacies and hospitals.

Significant violations included the identification of counterfeit Atorvastatin Calcium Tablets attributed to Pfizer Pharmaceutical Co., Ltd. Other widespread issues spanned multiple product types, from injectable medications to Traditional Chinese Medicine (TCM) ingredients. Common deficiencies included the presence of visible foreign matter, deviations in product appearance, failures in identification and chromatographic tests, and non-compliance with specifications for moisture content, relative density, total ash, acid-insoluble ash, and active ingredient determination. Companies such as Guangdong Nanguo Pharmaceutical Co., Ltd., Jiangxi Pharmaceutical Co., Ltd., and several local TCM producers were among those whose products were found substandard.

All localities are mandated to investigate and address these violations in accordance with the "Drug Administration Law of the People's Republic of China" and other pertinent regulations. The required actions involve enforcement measures against the non-compliant entities to ensure public medication safety and uphold drug quality standards.

Company: https://www.globalkeysolutions.net/companies/bozhou-baisheng-pharmaceutical-co-ltd/65aea31c-4394-4b8d-bdd1-652d4cd638f1/